BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
Beijing-based biotechnology company, BeiGene, was granted approval by China’s National Medical Products Administration (NMPA) on April 15th to administer their novel anti-PD-1 antibody, tislelizumab, to patients with second-line esophageal squamous cell carcinoma (ESCC). ESCC is by far the world’s most pervasive esophageal cancer accounting for about 90% of roughly 456,000 recorded cases each year.
It's free! Log in now to read
LATEST
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115